These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 19969453)

  • 1. Optimization of piperidyl-ureas as inhibitors of soluble epoxide hydrolase.
    Eldrup AB; Soleymanzadeh F; Farrow NA; Kukulka A; De Lombaert S
    Bioorg Med Chem Lett; 2010 Jan; 20(2):571-5. PubMed ID: 19969453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-based optimization of arylamides as inhibitors of soluble epoxide hydrolase.
    Eldrup AB; Soleymanzadeh F; Taylor SJ; Muegge I; Farrow NA; Joseph D; McKellop K; Man CC; Kukulka A; De Lombaert S
    J Med Chem; 2009 Oct; 52(19):5880-95. PubMed ID: 19746975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of substituted nicotinamides as inhibitors of soluble epoxide hydrolase.
    Taylor SJ; Soleymanzadeh F; Eldrup AB; Farrow NA; Muegge I; Kukulka A; Kabcenell AK; De Lombaert S
    Bioorg Med Chem Lett; 2009 Oct; 19(20):5864-8. PubMed ID: 19758802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.
    Shen HC; Ding FX; Wang S; Xu S; Chen HS; Tong X; Tong V; Mitra K; Kumar S; Zhang X; Chen Y; Zhou G; Pai LY; Alonso-Galicia M; Chen X; Zhang B; Tata JR; Berger JP; Colletti SL
    Bioorg Med Chem Lett; 2009 Jul; 19(13):3398-404. PubMed ID: 19481932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.
    Shen HC; Ding FX; Deng Q; Xu S; Chen HS; Tong X; Tong V; Zhang X; Chen Y; Zhou G; Pai LY; Alonso-Galicia M; Zhang B; Roy S; Tata JR; Berger JP; Colletti SL
    Bioorg Med Chem Lett; 2009 Sep; 19(18):5314-20. PubMed ID: 19682899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A strategy of employing aminoheterocycles as amide mimics to identify novel, potent and bioavailable soluble epoxide hydrolase inhibitors.
    Shen HC; Ding FX; Deng Q; Xu S; Tong X; Zhang X; Chen Y; Zhou G; Pai LY; Alonso-Galicia M; Roy S; Zhang B; Tata JR; Berger JP; Colletti SL
    Bioorg Med Chem Lett; 2009 Oct; 19(19):5716-21. PubMed ID: 19700315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploration of secondary and tertiary pharmacophores in unsymmetrical N,N'-diaryl urea inhibitors of soluble epoxide hydrolase.
    Anandan SK; Gless RD
    Bioorg Med Chem Lett; 2010 May; 20(9):2740-4. PubMed ID: 20363133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid synthesis of an array of trisubstituted urea-based soluble epoxide hydrolase inhibitors facilitated by a novel solid-phase method.
    Kowalski JA; Swinamer AD; Muegge I; Eldrup AB; Kukulka A; Cywin CL; De Lombaert S
    Bioorg Med Chem Lett; 2010 Jun; 20(12):3703-7. PubMed ID: 20472432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro metabolism of the mammalian soluble epoxide hydrolase inhibitor, 1-cyclohexyl-3-dodecyl-urea.
    Watanabe T; Morisseau C; Newman JW; Hammock BD
    Drug Metab Dispos; 2003 Jul; 31(7):846-53. PubMed ID: 12814960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-based optimization of cyclopropyl urea derivatives as potent soluble epoxide hydrolase inhibitors for potential decrease of renal injury without hypotensive action.
    Takai K; Nakajima T; Takanashi Y; Sone T; Nariai T; Chiyo N; Nakatani S; Ishikawa C; Yamaguchi N; Fujita K; Yamada K
    Bioorg Med Chem; 2014 Mar; 22(5):1548-57. PubMed ID: 24530032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage.
    Zhao X; Yamamoto T; Newman JW; Kim IH; Watanabe T; Hammock BD; Stewart J; Pollock JS; Pollock DM; Imig JD
    J Am Soc Nephrol; 2004 May; 15(5):1244-53. PubMed ID: 15100364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring the size of the lipophilic unit of the soluble epoxide hydrolase inhibitors.
    Codony S; Valverde E; Leiva R; Brea J; Isabel Loza M; Morisseau C; Hammock BD; Vázquez S
    Bioorg Med Chem; 2019 Oct; 27(20):115078. PubMed ID: 31488357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic screening of soluble epoxide hydrolase inhibitors in dogs.
    Tsai HJ; Hwang SH; Morisseau C; Yang J; Jones PD; Kasagami T; Kim IH; Hammock BD
    Eur J Pharm Sci; 2010 Jun; 40(3):222-38. PubMed ID: 20359531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and structure-activity relationship of piperidine-derived non-urea soluble epoxide hydrolase inhibitors.
    Pecic S; Pakhomova S; Newcomer ME; Morisseau C; Hammock BD; Zhu Z; Rinderspacher A; Deng SX
    Bioorg Med Chem Lett; 2013 Jan; 23(2):417-21. PubMed ID: 23237835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacophoric modeling and atom-based 3D-QSAR of novel 1-aryl-3-(1-acylpiperidin-4-yl) urea as human soluble epoxide hydrolase inhibitors (sEHIs).
    Das N; Dhanawat M; Kulshrestha A; Shrivastava SK
    Med Chem; 2011 Nov; 7(6):581-92. PubMed ID: 22313298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peptidyl-urea based inhibitors of soluble epoxide hydrolases.
    Morisseau C; Newman JW; Tsai HJ; Baecker PA; Hammock BD
    Bioorg Med Chem Lett; 2006 Oct; 16(20):5439-44. PubMed ID: 16908134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and biological activity of 1,3-disubstituted ureas as potent inhibitors of the soluble epoxide hydrolase of increased water solubility.
    Kim IH; Morisseau C; Watanabe T; Hammock BD
    J Med Chem; 2004 Apr; 47(8):2110-22. PubMed ID: 15056008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of adamantane alterations on soluble epoxide hydrolase inhibition potency, physical properties and metabolic stability.
    Burmistrov V; Morisseau C; Harris TR; Butov G; Hammock BD
    Bioorg Chem; 2018 Feb; 76():510-527. PubMed ID: 29310082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral treatment of rodents with soluble epoxide hydrolase inhibitor 1-(1-propanoylpiperidin-4-yl)-3-[4-(trifluoromethoxy)phenyl]urea (TPPU): Resulting drug levels and modulation of oxylipin pattern.
    Ostermann AI; Herbers J; Willenberg I; Chen R; Hwang SH; Greite R; Morisseau C; Gueler F; Hammock BD; Schebb NH
    Prostaglandins Other Lipid Mediat; 2015 Sep; 121(Pt A):131-7. PubMed ID: 26117215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble epoxide hydrolase inhibitors: a patent review.
    Shen HC
    Expert Opin Ther Pat; 2010 Jul; 20(7):941-56. PubMed ID: 20429668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.